Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 429.40
-1.70 (-0.39%)
At close: Jun 1, 2026
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 165.08 billion as of June 1, 2026. Its market cap has decreased by -59.96% in one year.
Market Cap
165.08B
Enterprise Value
167.05B
Revenue
22.69B
Ranking
n/a
PE Ratio
92.10
Stock Price
429.40
Market Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 165.08B, an increase of 489,672.20%. That is a compound annual growth rate of 291.56%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 29, 2026 | 165.08B | -18.37% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GlaxoSmithKline Pharmaceuticals | 374.17B |
| J. B. Chemicals & Pharmaceuticals | 348.81B |
| AstraZeneca Pharma India | 216.79B |
| Granules India | 191.37B |
| Rubicon Research | 165.67B |
| Jubilant Pharmova | 157.38B |
| Caplin Point Laboratories | 154.31B |
| Viyash Scientific | 113.07B |